Log In
Print this Print this

Taltz, ixekizumab (LY2439821)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionHumanized mAb against IL-17A
Molecular Target Interleukin-17A (IL-17A)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today